Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Accumulated Expenses (2021 - 2025)

ARS Pharmaceuticals' Accumulated Expenses history spans 3 years, with the latest figure at $2.3 million for Q4 2024.

  • For Q4 2024, Accumulated Expenses changed N/A year-over-year to $2.3 million; the TTM value through Dec 2024 reached $2.3 million, changed N/A, while the annual FY2024 figure was $2.3 million, N/A changed from the prior year.
  • Accumulated Expenses for Q4 2024 was $2.3 million at ARS Pharmaceuticals, up from $718000.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $5.8 million in Q1 2021 and bottomed at $404000.0 in Q1 2022.
  • The 3-year median for Accumulated Expenses is $2.2 million (2021), against an average of $2.5 million.
  • The largest YoY upside for Accumulated Expenses was 72.55% in 2022 against a maximum downside of 93.03% in 2022.
  • A 3-year view of Accumulated Expenses shows it stood at $4.6 million in 2021, then crashed by 84.41% to $718000.0 in 2022, then skyrocketed by 219.36% to $2.3 million in 2024.
  • Per Business Quant, the three most recent readings for SPRY's Accumulated Expenses are $2.3 million (Q4 2024), $718000.0 (Q3 2022), and $597000.0 (Q2 2022).